Cas9 Stable Cell Line - 22RV1

The Cas9-stable 22RV1 cell line is a genetically engineered derivative of the human prostate cancer cell line 22RV1; its parental cells were originally derived from a primary prostatic epithelial carcinoma xenograft established in a mouse model. This modified cell line is capable of stably expressing CRISPR-associated protein 9 (Cas9), a critical component of the CRISPR-Cas9 genome editing system. The parental 22RV1 cells were derived from a 66-year-old male patient with prostate cancer and are characterized by their androgen receptor-positive status and expression of prostate-specific antigen (PSA), making them a highly relevant model for studying hormone-responsive malignancies. The stable integration of the Cas9 nuclease within this cell line ensures its continuous and long-term expression—eliminating the need for repetitive transfection procedures—thereby significantly enhancing experimental reproducibility. Distinguished by its robust proliferative capacity in standard culture media, high gene editing efficiency, and excellent compatibility with various sgRNA delivery methods, the Cas9-stable 22RV1 cell line has emerged as a powerful model in the fields of prostate cancer research and genetic manipulation.

In the context of prostate cancer research, this cell line facilitates high-throughput functional genomics screens, enabling the identification of key genes that drive castration resistance, tumor metastasis, or therapeutic sensitivity; this is crucial for gaining a deeper understanding of androgen receptor signaling pathways or DNA repair mechanisms (e.g., those involving BRCA mutations). Researchers can utilize this cell line to construct isogenic disease models—for instance, by knocking out tumor suppressor genes (such as PTEN) or introducing oncogenic mutations—thereby allowing for the precise evaluation of drug efficacy within a well-defined genetic background. In the realm of drug discovery and development, this cell line supports the validation of specific molecular targets and drug mechanisms of action through the rapid generation of gene knockout or knock-in mutant variants. Given its specific cellular background derived from prostatic tissue, this cell line holds immense value for exploring the interactions between tumors and the immune system, deciphering mechanisms of resistance to immunotherapy, and discovering novel biomarkers.